In June 2022, LLS made an equity investment in Faron Pharmaceuticals to "Support Clinical Development of the Bexmarilimab Program for Leukemia Indications."
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. A Phase 1 study in AML (BEXMAB) has been cleared by the FDA and Finnish Medicines Agency and is currently enrolling patients (NCT05428969).
For more information about Faron, visit www.faron.com/.
- June 28, 2022 - announced a private placement to a limited number of institutional and other investors to raise EUR 5 million including The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP).
- June 8 2022 - announced that the first patient has been dosed in its Phase I/II BEXMAB study, which will investigate bexmarilimab in combination with standard of care in multiple hematologic malignancies
- May 16 2022 - announced that the FDA and Finnish Medicines Agency have cleared Faron’s IND application to begin the Company sponsored BEXMAB study, a novel Phase I/II study to assess safety, tolerability and preliminary efficacy of bexmarilimab in combination with standard of care therapy in patients with relapsed AML, MDS, or CMML.
- May 12, 2022 - announced that preclinical data to support the Company's upcoming clinical trials investigating the potential of bexmarilimab in combination with standard of care (SoC) in hematologic cancers will be presented at the EHA2022 Congress in Vienna, Austria, from June 9-12, 2022.